The overlooked pandemic of antimicrobial resistance
20 January 2022
As COVID-19 rages on, the pandemic of antimicrobial resistance (AMR) continues in the shadows. The toll taken by AMR on patients and their families is largely invisible but is reflected in prolonged bacterial infections that extend hospital stays and cause needless deaths.
Moreover, AMR disproportionately affects poor individuals who have little access to second-line, more expensive antibiotics that could work when first-line drugs fail.
Further reading: The Lancet
Author(s): Ramanan Laxminarayan
Effective Surveillance
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
